Why Insmed Shares Sank

Don't let it get away!

Keep track of the stocks that matter to you.

Help yourself with the Fool's FREE and easy new watchlist service today.

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of biotechnology company Insmed (NASDAQ: INSM  ) plunged 15% today after a phase 3 trial of the company's experimental lung-infection drug Arikace disappointed Wall Street.  

So what: The trial showed that patients taking the once-daily drug Arikace had a smaller improvement in lung capacity than those treated with Novartis' (NYSE: NVS  ) twice-daily competitor TOBI, triggering plenty of investor concern over Arikace's position in the market. While Insmed said that the trial met its main objective of showing that Arikace was not statistically inferior to TOBI, the lackluster results -- it isn't exactly superior -- suggest that the drug's sales potential is limited.

Now what: Management expects to file for regulatory approval in Canada and Europe during the first half of 2014.

"[I]f approved by the EMA and Health Canada, we look forward to bringing ARIKACE to market in order to benefit the thousands of [cystic fibrosis] patients in need of an effective and convenient treatment for these chronic and often life-threatening Pseudomonas aeruginosa lung infections," said CEO Will Lewis.

Given the competitive and regulatory risks that continue to surround Insmed, however, only biotech-savvy Fools should even consider buying into that optimism.  

While you can certainly make quick gains in speculative biotech stocks, the best investing approach is to choose great companies and stick with them for the long term. The Motley Fool's free report "3 Stocks That Will Help You Retire Rich" names stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.

Read/Post Comments (1) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On July 01, 2013, at 11:41 AM, jad9000 wrote:

    First, you might want to wait until the end of the day to start yapping about the share price. Second, there was little to know statistical difference in the results between TOBI and Arikace but TOBI users don't take their twice daily doses at a factor of 40% to 50%. So, in reality, the comparisons are apples to oranges. IF TOBI users took their doses correctly they would be same same, but, in fact, they don't. A single dose, comparable product will likely be far more popular with both treating physicians and patients and alleviate the chronic non-compliance of patients. In addition, after a relatively short period of time TOBI becomes ineffective. Arikace may well start out as a continuation of therapy when TOBI quits working - and it does. This is sti;; a very large market. And, finally, you managed to leave out the NTM indication - which Arikace is also targeting and has zero competition in. In the future you might want to tell the whole story and not a fraction of it.

Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2518452, ~/Articles/ArticleHandler.aspx, 9/28/2016 10:40:19 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,236.31 8.01 0.04%
S&P 500 2,160.12 0.19 0.01%
NASD 5,305.56 -0.15 0.00%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/28/2016 10:24 AM
INSM $14.59 Down -0.44 -2.93%
Insmed CAPS Rating: **
NVS $81.08 Up +0.20 +0.25%
Novartis CAPS Rating: ****